Company news

Share this article:
Altor BioScience Corporation entered into an agreement with Genentech for exclusive, worldwide rights to develop and commercialize a class of antibody-based tissue factor antagonists. Altor plans on initiating a multi-center, Phase II clinical study later this year, using the lead therapeutic antibody known as ALT-836 for the treatment of acute respiratory distress syndrome and acute lung injury. Financial terms of the licensing transaction were not disclosed.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.